299. 嚢胞性線維症
[臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03066453
(ClinicalTrials.gov)
June 13, 201723/2/2017Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic FibrosisEvaluation of an Antibiotic Treatment With 14 Days of Intravenous Tobramycin Versus the Same Antibiotic Associated With 5 Days of Intravenous Tobramycin Followed by Tobramycin Aerosol for 9 Days in Cystic Fibrosis.Cystic FibrosisDrug: Tobi Inhalant Product;Drug: NebcinUniversity Hospital, LilleNULLRecruiting8 YearsN/AAll97Phase 3France
2NCT01337219
(ClinicalTrials.gov)
April 201113/4/2011Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic FibrosisPharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaide® in Patients With Cystic Fibrosis.Cystic FibrosisDrug: TobramycinErempharmaUniversity of Lyon;Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfant (EPICIME);Clininfo;Hospices Civils de LyonRecruiting16 YearsN/ABoth36Phase 1;Phase 2France
3NCT01288170
(ClinicalTrials.gov)
February 20101/2/2011Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®Cystic FibrosisDrug: Nebcinal Tobi;Drug: Tobi NebcinalErempharmaHopitaux de Lyon;University of LyonRecruiting6 YearsN/ABoth12N/AFrance
4EUCTR2009-013660-39-FR
(EUCTR)
10/09/200927/11/2009Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré par Aeroneb® Idehaler® et Tobi® 300mg/5ml administré par Pari LC Plus ®Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré par Aeroneb® Idehaler® et Tobi® 300mg/5ml administré par Pari LC Plus ® Mucoviscidose
MedDRA version: 12.0;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung
Product Name: Nebcinal
INN or Proposed INN: tobramycine
Trade Name: Tobi
Product Name: Tobi
INN or Proposed INN: tobramycine
Erempharma SASNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France
5EUCTR2007-003868-22-FR
(EUCTR)
19/03/200820/12/2007ASSESMENT OG EFFICACY AND TOLERABILITY OF INHABLED TOBRAMYCIN VS PLACEBO IN CYSTIC FIBROSIS PATIENTS REVEIVING ANTIBIOTHERAPY FOR 28 DAYS FOR PSEUDOMONAS AERUGINOSA PRIMO COLONISATION. - NEBCINAL 01-07ASSESMENT OG EFFICACY AND TOLERABILITY OF INHABLED TOBRAMYCIN VS PLACEBO IN CYSTIC FIBROSIS PATIENTS REVEIVING ANTIBIOTHERAPY FOR 28 DAYS FOR PSEUDOMONAS AERUGINOSA PRIMO COLONISATION. - NEBCINAL 01-07 Assessment of microbiological efficacy and tolerability of inhaled tobramycin vs placebo in cystic fibrosis patients, primo colonised by Pseudomonas aeruginosa justified inhaled antiobiotherapeutical treatment during 28 days. Product Code: NEB/01-07Laboratoire ErempharmaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2014-003882-10-FR
(EUCTR)
29/07/2015Evaluation of the efficacy of antibiotic treatments associated with the Nebcine® as intravenous injection only and / or monitoring of aerosols of Tobi® in order to optimize the therapeutic management of exacerbations in patients with cystic fibrosis .Evaluation of the effectiveness of a treatment involving one (or several ) antibiotic (s) with 14-day tobramycin ( Nebcine® ) by intravenous injection versus the same antibiotic treatment (s ) associated with only 5 days of tobramycin ( Nebcine® ) by intravenous injection followed tobramycin aerosol ( Tobi® ) for 9 days in the context of cystic fibrosis mucoviscidosis or cystic fibrosis
MedDRA version: 18.0;Level: LLT;Classification code 10068288;Term: Cystic fibrosis pulmonary exacerbation;System Organ Class: 100000004862;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Trade Name: NEBCINE
Product Name: NEBCINE
Other descriptive name: TOBRAMYCIN
Trade Name: NEBCINE
Product Name: NEBCINE
Other descriptive name: TOBRAMYCIN
Trade Name: NEBCINE
Product Name: NEBCINE
Other descriptive name: TOBRAMYCIN
Trade Name: NEBCINE
Product Name: NEBCINE
Other descriptive name: TOBRAMYCIN
Trade Name: TOBI
Product Name: TOBI
Other descriptive name: TOBRAMYCIN
CHRU de LilleNULLNAFemale: yes
Male: yes
Phase 2France
7EUCTR2010-023533-34-FR
(EUCTR)
14/12/2010Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré par Aeroneb® Idehaler® et Tobi® 300mg/5ml administré par Pari LC Plus ® /Pulmoaid ® chez des patients atteints de mucoviscidose.Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré par Aeroneb® Idehaler® et Tobi® 300mg/5ml administré par Pari LC Plus ® /Pulmoaid ® chez des patients atteints de mucoviscidose. Mucoviscidose
MedDRA version: 12.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung
Product Name: Nebcinal
Product Code: Nebcinal
Trade Name: Tobi
Product Name: Tobi
EREMPHARMA SASNULLNAFemale: yes
Male: yes
Phase 1France